News

The partnership will utilise Accutar’s artificial intelligence (AI) platform and Evommune’s expertise to design and develop novel oral small molecule treatments for targets, which are the root cause

The Hemophilia A programme integrates the Sernova Cell Pouch with a patient’s cells, eliminating the need for immunosuppression medications. This treatment aims to substitute Factor VIII (FVIII), a

The company has filed the applications based on Revascor’s data from a randomised, blinded, controlled prospective study carried out at a single centre in the US involving 19

A therapy platform developed by T3 Pharma using engineered Yersinia enterocolitica bacteria, delivers immune-modulating proteins to cancer cells and tumour micro-environments, sparing healthy tissues. The bacteria can be

Claimed to be the first vaccine against the disease to receive FDA’s marketing approval, IXCHIQ uses Albumedix’ Recombumin. Recombumin is an animal origin-free recombinant human albumin and is

The oral CDK2 inhibitor from Ensem is an investigational new drug (IND) application-ready asset. BeiGene R&D global head Lai Wang said: “We are committed to developing novel molecules

The clinical-stage long-acting human IL-7, NT-I7 is being developed in oncologic and immunologic indications. In these indications, T cell amplification and increased functionality are expected to provide clinical

EBGLYSS is intended for patients aged 12 years and above who are candidates for systemic therapy. The company plans to begin selling the product in Germany initially and

Homology Medicines will issue shares of its common stock to Q32 Bio stockholders as part of the merger deal, in return for cancelling Q32 Bio’s capital stock. Pre-merger